How Brenner was paid
$1.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Dr. Martin B. BrennerChief Executive Officer and Chief Scientific Officer | $539,366 | $799,272 | $161,411 | $9,858 | $1,509,907 |
| Felipe DuranChief Financial Officer | $371,319 | $293,447 | $89,116 | $16,199 | $770,081 |
| Marc BanjakChief Legal Officer | $366,932 | $245,983 | $88,130 | $11,858 | $712,903 |
What changed and why
- $1.5M$1,509,907 was CEO total compensation in fiscal 2025, versus $1,271,286 in fiscal 2024.
- $799K$799,272 was the CEO’s option-award compensation in fiscal 2025.
- 50%50% of base salary was Dr. Brenner’s fiscal 2025 bonus target under his amended employment agreement.
- 91%91% of votes cast supported the named executive officers’ compensation at the 2024 annual meeting.
- 150%150% of target was the cap on annual cash incentive payments.
- No executive received a fiscal 2025 stock award or cash bonus in the Summary Compensation Table.
Other iBio proxy statements
- 2026 proxy statement
Dr. Martin B. Brenner paid $2.1M (+42% on the year).
Filed Sep 04, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.